

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Myelodysplastic syndrome (deletion 5q) - lenalidomide

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation on the draft scope, consultees highlighted that without adjustments, QALYs gained in the mostly elderly myelodysplastic syndromes patients are likely to be lower than those gained in younger populations which could represent a potential equality issue. The response of more elderly patients to treatment depends on other factors, such as comorbidities, and is not directly related to age alone.

Attendees at the Scoping Workshop agreed that this was not an equalities issue per se as the Method's Guide states that 'The Institute considers equity in terms of how the effects of a health technology may deliver differential benefits across the population.'

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This issue does not need to be addressed by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A - No changes were made to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Frances Sutcliffe

Date: 11 November 2012